Key result
Every-other-day rosuvastatin was tolerated by 72.5% of patients with prior statin intolerance and reduced mean LDL-C by 34.5% (p < 0.001).
Why the study?
Does every-other-day rosuvastatin reduce LDL-C and allow for tolerability in patients with prior statin intolerance?
Cohort (n=51)
Yes
Does every-other-day rosuvastatin reduce LDL-C and allow for tolerability in patients with prior statin intolerance?
p-value: p=< 0.001
Every-other-day rosuvastatin dosing is tolerated by the majority of patients with prior statin intolerance and significantly reduces LDL-C.
No takes yet. Share an insight, caveat, or question.
May support every-other-day dosing in statin-intolerant patients; hypothesis-generating and requires randomized confirmation before practice change.
Backes et al. (2008) conducted a cohort in Prior statin intolerance (n=51). Every-other-day rosuvastatin was evaluated on Mean LDL-C decrease (p=< 0.001). Every-other-day rosuvastatin was tolerated by 72.5% of patients with prior statin intolerance and reduced mean LDL-C by 34.5% (p < 0.001).
Synapse has enriched one closely related paper. Consider it for comparative context: